Free Trial
→ Elon’s Terrifying Warning Forces Trump To Take Action (From American Hartford Gold) (Ad) Buy BNTX Stock  Free BNTX Stock Alerts

BioNTech (BNTX) Financials

BioNTech logo
$101.10 -3.84 (-3.66%)
Closing price 04:00 PM Eastern
Extended Trading
$101.16 +0.07 (+0.06%)
As of 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for BioNTech

Annual Income Statements for BioNTech

This table shows BioNTech's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -103 -55 -201 19 11,649 10,093 1,029 -689
Consolidated Net Income / (Loss)		 -103 -55 -201 19 11,649 10,093 1,029 -689
Net Income / (Loss) Continuing Operations		 -103 -55 -201 19 11,649 10,093 1,029 -689
Total Pre-Tax Income 		-103 -55 -201 -178 17,030 13,858 1,312 -701
Total Operating Income		 -74 -62 -204 -101 17,298 13,525 764 -1,360
Total Gross Profit		 63 130 102 517 18,183 15,315 3,561 2,287
Total Revenue		 74 146 122 589 21,478 18,519 4,225 2,848
Operating Revenue		 74 146 122 589 21,478 18,519 4,225 2,848
Total Cost of Revenue		 11 16 20 72 3,295 3,204 663 560
Operating Cost of Revenue		 11 16 20 72 3,295 3,204 663 560
Total Operating Expenses		 136 192 305 617 884 1,790 2,797 3,648
Selling, General & Admin Expense		 28 30 51 115 313 515 548 550
Marketing Expense		 7.93 3.48 3.03 18 57 64 69 70
Research & Development Expense		 103 164 254 788 1,074 1,644 1,972 2,333
Other Operating Expenses / (Income)		 -2.48 -5.35 -2.24 -303 -560 -434 208 694
Total Other Income / (Expense), net		 -30 7.09 2.36 -77 -269 333 548 659
Interest Expense		 32 2.02 2.24 79 345 20 26 28
Interest & Investment Income		 2.56 9.21 4.60 1.95 77 353 575 687
Income Tax Expense		 0.05 0.69 -0.22 -197 5,380 3,765 283 -13
Basic Earnings per Share		 ($0.61) ($0.25) ($0.85) $0.06 $42.18 $41.49 $4.28 ($2.87)
Weighted Average Basic Shares Outstanding		 - - - 241.52B 246.81M 240.99M 237.73M 239.97M
Diluted Earnings per Share		 ($0.61) ($0.25) ($0.85) $0.06 $39.63 $40.41 $4.24 ($2.87)
Weighted Average Diluted Shares Outstanding		 - - - 241.52B 246.81M 240.99M 237.73M 239.97M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 241.52B 246.81M 240.99M 237.73M 239.97M

Quarterly Income Statements for BioNTech

No quarterly income statements for BioNTech are available.

Annual Cash Flow Statements for BioNTech

This table details how cash moves in and out of BioNTech's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -128 275 121 900 473 13,033 6,313 809
Net Cash From Operating Activities		 -63 -67 -223 -16 1,007 13,404 1,558 410
Net Cash From Continuing Operating Activities		 -58 -67 -223 -16 1,022 13,404 1,558 410
Net Income / (Loss) Continuing Operations		 -103 -55 -201 -178 17,030 10,093 1,029 -689
Consolidated Net Income / (Loss)		 -103 -55 -201 -178 17,030 10,093 1,029 -689
Depreciation Expense		 13 25 38 47 85 132 203 308
Non-Cash Adjustments To Reconcile Net Income		 35 9.09 35 230 -22 3,088 194 4.76
Changes in Operating Assets and Liabilities, net		 -2.44 -47 -94 -116 -16,071 91 132 785
Net Cash From Investing Activities		 -63 -76 -87 -177 -641 50 5,572 401
Net Cash From Continuing Investing Activities		 -23 -76 -87 -177 -622 50 5,572 401
Acquisitions		 0.00 0.00 -6.85 -74 -24 0.00 -373 0.00
Sale of Property, Plant & Equipment		 6.24 0.81 0.00 1.47 - 0.64 5,945 401
Net Cash From Financing Activities		 -1.97 418 430 1,093 107 99 -817 -2.38
Net Cash From Continuing Financing Activities		 -1.97 418 430 1,093 107 99 -817 -2.38
Repayment of Debt		 -1.97 -2.46 -3.48 -17 -75 -20 -0.11 -2.38
Repurchase of Preferred Equity		 - - - - 0.00 - -817 0.00
Issuance of Debt		 0.00 6.41 12 191 0.00 0.86 0.33 0.00

Quarterly Cash Flow Statements for BioNTech

No quarterly cash flow statements for BioNTech are available.

Annual Balance Sheets for BioNTech

This table presents BioNTech's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 747 895 2,832 17,917 24,904 25,450 23,320
Total Current Assets		 514 629 2,036 17,059 23,452 21,601 19,464
Cash & Equivalents		 471 583 1,478 1,916 14,844 12,902 10,105
Accounts Receivable		 22 13 202 14,014 7,644 2,385 1,515
Inventories, net		 6.63 13 78 569 470 396 293
Current Deferred & Refundable Income Taxes		 1.02 0.85 1.10 0.45 0.43 198 52
Other Current Assets		 13 17 276 128 291 316 231
Other Current Nonoperating Assets		 0.38 1.89 - 432 203 5,404 7,268
Plant, Property, & Equipment, net		 76 104 277 365 652 838 968
Plant, Property & Equipment, gross		 76 104 277 365 652 838 968
Total Noncurrent Assets		 158 162 519 493 800 3,011 2,889
Goodwill		 - - - - 65 401 394
Intangible Assets		 101 100 200 229 170 889 818
Noncurrent Deferred & Refundable Income Taxes		 - 0.00 197 0.00 246 90 85
Other Noncurrent Operating Assets		 57 62 122 264 319 1,630 1,592
Total Liabilities & Shareholders' Equity		 747 895 2,832 17,917 24,904 25,450 23,320
Total Liabilities		 442 341 1,157 4,456 3,449 3,054 3,228
Total Current Liabilities		 144 155 740 3,940 3,157 2,290 2,612
Short-Term Debt		 9.46 5.96 11 - 840 459 1,494
Accounts Payable		 48 23 125 181 218 392 442
Current Deferred & Payable Income Tax Liabilities		 0.34 0.17 0.00 1,776 637 581 4.66
Other Current Liabilities		 87 126 604 1,984 1,461 858 671
Total Noncurrent Liabilities		 297 186 416 516 292 763 616
Long-Term Debt		 - 77 282 - 6.53 43 49
Capital Lease Obligations		 - - - 194 188 211 222
Noncurrent Deferred & Payable Income Tax Liabilities		 - 0.00 0.24 80 18 44 44
Other Noncurrent Operating Liabilities		 297 109 134 241 79 465 302
Total Equity & Noncontrolling Interests		 306 554 1,676 13,461 21,455 22,396 20,092
Total Preferred & Common Equity		 305 554 1,676 13,461 21,455 22,396 20,092
Total Common Equity		 305 554 1,676 13,461 21,455 22,396 20,092
Common Stock		 221 261 301 279 266 275 257
Retained Earnings		 - - -500 11,185 20,148 21,862 19,768
Treasury Stock		 0.00 -6.20 -5.86 -4.30 -5.67 -12 -8.90
Other Equity Adjustments		 365 776 1,881 2,001 1,048 271 76

Quarterly Balance Sheets for BioNTech

No quarterly balance sheets for BioNTech are available.

Annual Metrics and Ratios for BioNTech

This table displays calculated financial ratios and metrics derived from BioNTech's official financial filings.

Metric 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% 97.33% -16.53% 383.42% 3,545.38% -13.78% -77.19% -32.59%
EBITDA Growth		 0.00% 40.10% -352.93% 67.77% 32,662.70% -21.44% -92.92% -208.83%
EBIT Growth		 0.00% 16.24% -229.96% 50.58% 17,284.74% -21.81% -94.35% -278.13%
NOPAT Growth		 0.00% 16.26% -230.47% 50.58% 16,893.19% -16.75% -93.92% -258.98%
Net Income Growth		 0.00% 46.50% -264.09% 109.23% 62,635.91% -13.36% -89.80% -166.92%
EPS Growth		 0.00% 50.98% -240.00% 107.06% 65,950.00% 1.96% -89.51% -167.68%
Operating Cash Flow Growth		 0.00% -6.72% -230.59% 92.60% 6,205.89% 1,231.12% -88.38% -73.70%
Free Cash Flow Firm Growth		 0.00% 0.00% -394.99% -41.05% 299.73% 1,250.12% -76.37% -119.56%
Invested Capital Growth		 0.00% 0.00% 131.81% 832.84% 2,204.34% -34.17% -35.48% -6.63%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - -
Gross Margin		 84.87% 89.27% 83.98% 87.70% 84.66% 82.70% 84.29% 80.32%
EBITDA Margin		 -82.51% -25.05% -135.91% -9.06% 80.94% 73.75% 22.88% -36.94%
Operating Margin		 -99.48% -42.21% -167.13% -17.08% 80.54% 73.03% 18.08% -47.77%
EBIT Margin		 -99.61% -42.28% -167.13% -17.08% 80.54% 73.03% 18.08% -47.77%
Profit (Net Income) Margin		 -139.53% -37.83% -165.01% 3.15% 54.24% 54.50% 24.36% -24.18%
Tax Burden Percent		 100.05% 101.26% 99.89% -10.43% 68.41% 72.83% 78.43% 98.17%
Interest Burden Percent		 140.01% 88.36% 98.84% 176.94% 98.45% 102.46% 171.80% 51.56%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 31.59% 27.17% 21.57% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -25.94% 200.58% 105.06% 9.78% -20.51%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -36.50% 211.59% 102.06% 7.06% -22.10%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 27.60% -46.67% -47.25% -5.09% 17.27%
Return on Equity (ROE)		 0.00% -18.02% -46.75% 1.67% 153.91% 57.81% 4.69% -3.24%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -685.42% -187.21% 17.22% 146.27% 52.91% -13.65%
Operating Return on Assets (OROA)		 0.00% -8.26% -24.80% -5.40% 166.73% 63.17% 3.03% -5.58%
Return on Assets (ROA)		 0.00% -7.39% -24.49% 1.00% 112.28% 47.14% 4.09% -2.82%
Return on Common Equity (ROCE)		 0.00% -17.90% -46.64% 1.67% 153.91% 57.81% 4.69% -3.24%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -18.08% -36.31% 1.11% 86.54% 47.04% 4.60% -3.43%
Net Operating Profit after Tax (NOPAT)		 -52 -43 -143 -70 11,833 9,850 599 -952
NOPAT Margin		 -69.64% -29.55% -116.99% -11.96% 55.09% 53.19% 14.18% -33.44%
Net Nonoperating Expense Percent (NNEP)		 0.00% -5.12% -12.03% 10.56% -11.01% 3.00% 2.72% 1.59%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - 43.80% 2.59% -4.36%
Cost of Revenue to Revenue		 15.13% 10.73% 16.02% 12.30% 15.34% 17.30% 15.71% 19.68%
SG&A Expenses to Revenue		 38.18% 20.64% 41.90% 19.49% 1.46% 2.78% 12.96% 19.31%
R&D to Revenue		 138.80% 112.12% 208.56% 133.73% 5.00% 8.88% 46.69% 81.94%
Operating Expenses to Revenue		 184.35% 131.48% 250.46% 104.79% 4.12% 9.66% 66.22% 128.10%
Earnings before Interest and Taxes (EBIT)		 -74 -62 -204 -101 17,298 13,525 764 -1,360
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -61 -37 -166 -53 17,383 13,657 967 -1,052
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.49 0.60 10.89 4.57 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.74 0.74 12.36 4.64 0.00 0.00 0.00
Price to Revenue (P/Rev)		 2.03 1.03 2.74 30.97 2.86 0.00 0.01 0.01
Price to Earnings (P/E)		 0.00 0.00 0.00 982.61 5.28 0.00 0.02 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 1.42% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.10% 18.96% 27,222.64% 4,046.07% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 34.77 5.28 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 28.96 2.78 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 3.44 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 3.45 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 5.05 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 59.32 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 58.80 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.00 0.00 0.15 0.18 0.01 0.05 0.03 0.09
Long-Term Debt to Equity		 0.00 0.00 0.14 0.17 0.01 0.01 0.01 0.01
Financial Leverage		 0.00 -1.54 -1.13 -0.76 -0.22 -0.46 -0.72 -0.78
Leverage Ratio		 0.00 2.44 1.91 1.67 1.37 1.23 1.15 1.15
Compound Leverage Factor		 0.00 2.15 1.89 2.96 1.35 1.26 1.97 0.59
Debt to Total Capital		 0.00% 0.00% 13.07% 14.90% 1.42% 4.60% 3.09% 8.07%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.93% 0.56% 0.00% 3.73% 1.99% 6.84%
Long-Term Debt to Total Capital		 0.00% 0.00% 12.14% 14.33% 1.42% 0.87% 1.10% 1.24%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.32% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 99.37% 86.93% 85.10% 98.58% 95.40% 96.91% 91.93%
Debt to EBITDA		 0.00 0.00 -0.50 -5.49 0.01 0.08 0.74 -1.68
Net Debt to EBITDA		 0.00 0.00 3.01 22.20 -0.10 -1.01 -12.61 7.93
Long-Term Debt to EBITDA		 0.00 0.00 -0.47 -5.29 0.01 0.01 0.26 -0.26
Debt to NOPAT		 0.00 0.00 -0.58 -4.16 0.02 0.11 1.19 -1.85
Net Debt to NOPAT		 0.00 0.00 3.50 16.82 -0.15 -1.40 -20.35 8.76
Long-Term Debt to NOPAT		 0.00 0.00 -0.54 -4.00 0.02 0.02 0.42 -0.28
Altman Z-Score		 0.00 0.72 0.61 9.86 14.41 4.65 2.38 1.99
Noncontrolling Interest Sharing Ratio		 0.00% 0.63% 0.23% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 0.00 3.56 4.05 2.75 4.33 7.43 9.43 7.45
Quick Ratio		 0.00 3.41 3.84 2.27 4.04 7.12 6.67 4.45
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 122 -361 -509 1,016 13,714 3,240 -634
Operating Cash Flow to CapEx		 -274.81% -201.66% -279.18% -16.03% 577.73% 3,812.93% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 60.37 -160.64 -6.40 2.94 678.26 122.56 -22.35
Operating Cash Flow to Interest Expense		 -1.97 -33.28 -99.25 -0.21 2.92 662.93 58.92 14.44
Operating Cash Flow Less CapEx to Interest Expense		 -2.69 -49.79 -134.80 -1.50 2.41 645.54 283.77 28.59
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.00 0.20 0.15 0.32 2.07 0.86 0.17 0.12
Accounts Receivable Turnover		 0.00 6.74 6.96 5.47 3.02 1.71 0.84 1.46
Inventory Turnover		 0.00 2.36 1.97 1.58 10.19 6.17 1.53 1.63
Fixed Asset Turnover		 0.00 1.93 1.35 3.09 66.88 36.43 5.67 3.15
Accounts Payable Turnover		 0.00 0.33 0.55 0.98 21.53 16.04 2.18 1.34
Days Sales Outstanding (DSO)		 0.00 54.18 52.48 66.77 120.79 213.44 433.25 249.94
Days Inventory Outstanding (DIO)		 0.00 154.35 184.87 230.41 35.83 59.18 238.19 224.40
Days Payable Outstanding (DPO)		 0.00 1,112.36 661.26 372.79 16.95 22.75 167.77 271.41
Cash Conversion Cycle (CCC)		 0.00 -903.83 -423.92 -75.61 139.68 249.87 503.67 202.92
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 0.00 -165 53 491 11,308 7,444 4,803 4,485
Invested Capital Turnover		 0.00 -1.77 -2.16 2.17 3.64 1.98 0.69 0.61
Increase / (Decrease) in Invested Capital		 0.00 -165 218 438 10,817 -3,864 -2,641 -318
Enterprise Value (EV)		 0.00 -320 -165 17,060 59,729 -13,772 -12,163 -8,313
Market Capitalization		 150 150 334 18,245 61,450 37 25 27
Book Value per Share		 $0.00 $30.46 $55.38 $0.01 $0.06 $86.93 $92.93 $84.52
Tangible Book Value per Share		 $0.00 $20.39 $45.35 $0.01 $0.05 $85.98 $87.58 $79.42
Total Capital		 0.00 307 637 1,969 13,656 22,490 23,110 21,857
Total Debt		 0.00 0.00 83 293 194 1,035 713 1,765
Total Long-Term Debt		 0.00 0.00 77 282 194 195 254 271
Net Debt		 0.00 -471 -499 -1,185 -1,722 -13,809 -12,189 -8,340
Capital Expenditures (CapEx)		 23 33 80 103 174 352 -5,945 -401
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -101 -103 -171 11,203 6,292 6,868 8,241
Debt-free Net Working Capital (DFNWC)		 0.00 369 480 1,307 13,118 21,136 19,770 18,346
Net Working Capital (NWC)		 0.00 369 474 1,296 13,118 20,296 19,311 16,852
Net Nonoperating Expense (NNE)		 52 12 59 -89 184 -243 -430 -264
Net Nonoperating Obligations (NNO)		 0.00 -472 -501 -1,185 -2,153 -14,011 -17,593 -15,608
Total Depreciation and Amortization (D&A)		 13 25 38 47 85 132 203 308
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -69.49% -84.56% -29.07% 52.16% 33.98% 162.56% 289.40%
Debt-free Net Working Capital to Revenue		 0.00% 253.06% 393.48% 221.85% 61.08% 114.13% 467.98% 644.24%
Net Working Capital to Revenue		 0.00% 253.06% 388.59% 219.97% 61.08% 109.59% 457.10% 591.77%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($0.85) $0.06 $0.00 $38.78 $3.87 ($2.87)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 241.52B 0.00 240.99M 237.73M 239.97M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($0.85) $0.06 $0.00 $37.77 $3.83 ($2.87)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 241.52B 0.00 240.99M 237.73M 239.97M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($0.85) $0.06 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 241.52B 0.00 240.99M 237.73M 239.97M
Normalized Net Operating Profit after Tax (NOPAT)		 -52 -43 -143 -70 11,833 9,850 599 -952
Normalized NOPAT Margin		 -69.64% -29.55% -116.99% -11.96% 55.09% 53.19% 14.18% -33.44%
Pre Tax Income Margin		 -139.46% -37.36% -165.19% -30.23% 79.29% 74.83% 31.06% -24.63%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 -2.30 -30.49 -90.75 -1.27 50.09 668.93 28.89 -47.97
NOPAT to Interest Expense		 -1.61 -21.31 -63.53 -0.89 34.27 487.18 22.66 -33.58
EBIT Less CapEx to Interest Expense		 -3.02 -46.99 -126.30 -2.56 49.59 651.54 253.74 -33.82
NOPAT Less CapEx to Interest Expense		 -2.32 -37.81 -99.08 -2.18 33.76 469.79 247.51 -19.43
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for BioNTech

No quarterly metrics and ratios for BioNTech are available.

Frequently Asked Questions About BioNTech's Financials

When does BioNTech's fiscal year end?

According to the most recent income statement we have on file, BioNTech's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has BioNTech's net income changed over the last 7 years?

BioNTech's net income appears to be on an upward trend, with a most recent value of -$688.65 million in 2024, rising from -$103.25 million in 2017. The previous period was $1.03 billion in 2023. See BioNTech's forecast for analyst expectations on what’s next for the company.

What is BioNTech's operating income?
BioNTech's total operating income in 2024 was -$1.36 billion, based on the following breakdown:
  • Total Gross Profit: $2.29 billion
  • Total Operating Expenses: $3.65 billion
How has BioNTech revenue changed over the last 7 years?

Over the last 7 years, BioNTech's total revenue changed from $73.99 million in 2017 to $2.85 billion in 2024, a change of 3,748.5%.

How much debt does BioNTech have?

BioNTech's total liabilities were at $3.23 billion at the end of 2024, a 5.7% increase from 2023, and a 630.7% increase since 2018.

How much cash does BioNTech have?

In the past 6 years, BioNTech's cash and equivalents has ranged from $470.96 million in 2018 to $14.84 billion in 2022, and is currently $10.10 billion as of their latest financial filing in 2024.

How has BioNTech's book value per share changed over the last 7 years?

Over the last 7 years, BioNTech's book value per share changed from 0.00 in 2017 to 84.52 in 2024, a change of 8,451.9%.


Related Companies

This page (NASDAQ:BNTX) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners
Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...
American Hartford Gold | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...
Crypto 101 Media | Sponsored
Most traders are panicking. We’re cashing in
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....
Crypto Swap Profits | Sponsored
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
Musk's warning signal: Prepare before the cascade begins
When Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...
InvestorPlace | Sponsored
Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Massive new energy source found in Utah
NEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...
Stansberry Research | Sponsored